Ligand to Report Third Quarter Financial Results on November 9, 2021
Ligand Pharmaceuticals (NASDAQ: LGND) will announce its financial results for the three and nine months ending September 30, 2021 on November 9, 2021, after market close. A conference call will be held on the same day at 4:30 p.m. Eastern time, featuring CEO John Higgins, President and COO Matt Foehr, and Executive VP and CFO Matt Korenberg. Ligand focuses on drug discovery and partnerships to create revenue streams, leveraging patented technologies like OmniAb® and Captisol®.
- Expected revenue generation from third quarter results.
- Strong partnerships with leading pharmaceutical companies.
- None.
Conference Call and Webcast Information
What: |
Ligand conference call to discuss third quarter 2021 financial results and provide general business updates |
|
|
|
|
Date: |
|
|
|
|
|
Time: |
|
|
|
|
|
Conference Call: |
Dial (833) 540-1167 within the |
|
|
Dial (929) 517-0358 outside the |
|
|
Conference ID is 5486177 |
|
|
|
|
Webcast: |
Live and replay webcast of the call are available here. |
About
Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory affairs and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology™ is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by traditional systems. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Roche, Jazz Pharmaceuticals, Sanofi, Janssen, Takeda, Gilead Sciences,
Follow Ligand on Twitter @Ligand_LGND.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026006038/en/
investors@ligand.com
(858) 550-7766
Twitter: @Ligand_LGND
LHA Investor Relations
bvoss@lhai.com
(310) 691-7100
Source:
FAQ
What date will Ligand Pharmaceuticals report its Q3 2021 financial results?
What time is the Ligand Pharmaceuticals conference call for Q3 2021 results?
Who will speak during the Ligand Pharmaceuticals Q3 2021 conference call?
What technologies does Ligand Pharmaceuticals utilize?
